drugset / Trial / NCT00892710
Trial of Poor Performance Status Patients (ToPPS)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
Timeline
- Start
- 2009-06
- Primary completion
- 2014-07
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |